Delaney substitute would tie state prescription prices to Medicare negotiations; industry calls it price control A Delaney substitute that mirrors Medicare negotiated prices and moves enforcement to the state health commissioner drew mixed reaction at the Senate committee: advocates called it consumer-focused while pharmaceutical representatives said it amounted to price controls. The committee voted to report the measure to finance.

Virginia is taking a bold step to lower prescription drug costs by aligning prices with Medicare, but the pharmaceutical industry warns it might lead to price controls.

Click to read more!

#VA #PharmaceuticalTransparency #ConsumerProtection #CitizenPortal #VirginiaPrescriptionPrices

Subcommittee opens hearing to probe prescription drug supply chain and affordability A House Energy and Commerce subcommittee opened a hearing to examine how manufacturers, PBMs, distributors, GPOs and community pharmacies affect drug prices and patient access; the chair cited recent PBM reform and warned the system often operates "as if in a black box."

A House subcommittee is pulling back the curtain on the complex prescription drug supply chain to tackle affordability and transparency—are you ready to uncover the truth behind your medication costs?

Learn more here!

#US #CommunityPharmacies #PharmaceuticalTransparency #CitizenPortal

Pharma trade association urges 'delinking' PBM pay from list prices and calls for broader supply‑chain scrutiny A pharmaceutical trade association witness told the council on Oct. 27 that PBMs' incentives are tied to list price and fees, and recommended separating PBM compensation from list prices — a policy described in testimony as 'delinking' — to reduce incentives to favor higher‑priced drugs.

A leading pharma trade association is pushing for a bold change in how pharmacy benefit managers are compensated, suggesting that separating their pay from drug list prices could lower costs for patients.

Learn more here!

#LA #CitizenPortal #PharmaceuticalTransparency #HealthcareReform

NAMI Kansas urges reforms to 340B drug pricing program for patient benefit NAMI Kansas calls for transparency and accountability in the 340B drug program.

Kansas patients are paying the price as the 340B drug pricing program strays from its mission to provide affordable medications, leaving vulnerable communities at risk.

Click to read more!

#KS #CitizenPortal #PatientCare #PharmaceuticalTransparency #HealthcareAccessibility #KansasHealthcare

Indiana amends audit and reporting requirements for pharmacy benefit managers Indiana updates compliance audit procedures for pharmacy benefit managers effective July 2025.

Indiana's new House Bill 1004 could revolutionize drug pricing by mandating annual audits of pharmacy benefit managers, aiming for transparency and potentially lower costs for patients.

Click to read more!

#IN #PharmaceuticalTransparency #CitizenPortal #HealthcareReform

Ten states enact pharmacy laws despite pharmaceutical industry opposition Recent legislation in ten states counters pharmacy contract restrictions amid industry pushback.

Vermont's Senate Health and Welfare Committee is tackling pharmaceutical restrictions that threaten health centers, with ten states already pushing back against industry pressures.

Learn more here

#VT #PharmaceuticalTransparency #CitizenPortal #VermontHealthCenters #HealthcareAccess

FDA defines prescription drug terms for market and pricing regulations FDA clarifies definitions for new drugs, pricing, and patient assistance programs.

Minnesota's Senate Bill 2477 is set to revolutionize prescription drug pricing, aiming to balance affordability with the need for innovation in the pharmaceutical industry.

Learn more here!

#MN #PrescriptionDrugPrices #PharmaceuticalTransparency #CitizenPortal #MinnesotaHealthcare

Minnesota amends drug reporting requirements for wholesale distributors effective January 2024 Minnesota updates drug reporting mandates for wholesale distributors starting January 2024.

A groundbreaking bill in Minnesota aims to revolutionize the pharmaceutical supply chain by demanding transparency that could reshape drug pricing and accessibility for millions.

Learn more here

#MN #DrugPricingReform #PharmaceuticalTransparency #CitizenPortal #HealthcareAccessibility

Senator explores cost transparency in medication with pharmaceutical society leadership Senator emphasizes need for transparency in medication costs to enhance patient care.

Senators in Georgia are demanding transparency in pharmaceutical costs as they tackle the financial burdens facing patients, especially those with chronic conditions.

Learn more here!

#GA #GeorgiaPatientCare #PharmaceuticalTransparency #CostEfficiency #CitizenPortal #HealthcareAccess

Oklahoma targets PBMs with fines and license suspensions for compliance failures Oklahoma enforces strict penalties on PBMs for violating pharmacy choice regulations.

Oklahoma lawmakers are taking a bold stand against Pharmacy Benefit Managers, proposing strict penalties to enhance transparency and protect patient access to medications.

Learn more here

#OK #ConsumerProtection #HealthcareAccess #CitizenPortal #PharmaceuticalTransparency